CIBC Asset Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$84M Buy
664,533
+144,752
+28% +$19.1M 0.18% 101
2026
Q1
$72.4M Sell
519,781
-12,339
-2% -$1.73M 0.18% 98
2025
Q4
$65.3M Buy
532,120
+128,992
+32% +$15.7M 0.16% 108
2025
Q3
$44.7M Sell
403,128
-5,835
-1% -$663K 0.13% 118
2025
Q2
$45.3M Sell
408,963
-28,874
-7% -$3.07M 0.14% 111
2025
Q1
$49.1M Sell
437,837
-10,444
-2% -$1.08M 0.16% 103
2024
Q4
$41.4M Buy
448,281
+8,911
+2% +$802K 0.14% 111
2024
Q3
$36.8M Buy
439,370
+22,624
+5% +$1.73M 0.12% 122
2024
Q2
$28.6M Buy
416,746
+2,860
+0.7% +$191K 0.1% 136
2024
Q1
$30.3M Sell
413,886
-29,573
-7% -$2.27M 0.11% 134
2023
Q4
$35.9M Sell
443,459
-3,137
-0.7% -$244K 0.13% 118
2023
Q3
$33.5M Buy
446,596
+30,871
+7% +$2.37M 0.14% 115
2023
Q2
$32M Sell
415,725
-13,985
-3% -$1.12M 0.12% 126
2023
Q1
$35.7M Sell
429,710
-22,373
-5% -$1.85M 0.14% 119
2022
Q4
$38.8M Sell
452,083
-69,662
-13% -$5.52M 0.16% 107
2022
Q3
$32.2M Buy
521,745
+4,559
+0.9% +$287K 0.14% 108
2022
Q2
$32M Sell
517,186
-4,706
-0.9% -$291K 0.13% 110
2022
Q1
$31M Buy
521,892
+47,938
+10% +$3.06M 0.11% 116
2021
Q4
$34.4M Buy
473,954
+20,113
+4% +$1.39M 0.13% 110
2021
Q3
$31.7M Buy
453,841
+147,614
+48% +$10.4M 0.13% 116
2021
Q2
$21.1M Buy
306,227
+4,582
+2% +$306K 0.09% 141
2021
Q1
$19.5M Sell
301,645
-2,667
-0.9% -$172K 0.08% 144
2020
Q4
$17.7M Buy
304,312
+15,951
+6% +$962K 0.08% 147
2020
Q3
$18.2M Buy
288,361
+74,308
+35% +$5.15M 0.09% 134
2020
Q2
$16.5M Sell
214,053
-52,708
-20% -$4.04M 0.1% 127
2020
Q1
$19.9M Sell
266,761
-283,255
-51% -$19.6M 0.14% 101
2019
Q4
$35.7M Buy
550,016
+45,382
+9% +$2.96M 0.2% 64
2019
Q3
$32M Buy
504,634
+165,965
+49% +$10.8M 0.19% 69
2019
Q2
$22.9M Buy
338,669
+9,778
+3% +$643K 0.14% 78
2019
Q1
$21.4M Buy
328,891
+12,157
+4% +$808K 0.13% 81
2018
Q4
$19.8M Buy
316,734
+12,698
+4% +$888K 0.15% 74
2018
Q3
$23.5M Sell
304,036
-29,872
-9% -$2.26M 0.15% 74
2018
Q2
$23.7M Buy
333,908
+168,382
+102% +$11.9M 0.15% 70
2018
Q1
$12.5M Sell
165,526
-1,369
-0.8% -$109K 0.08% 106
2017
Q4
$12M Buy
166,895
+5,495
+3% +$417K 0.07% 115
2017
Q3
$13.1M Sell
161,400
-4,263
-3% -$326K 0.08% 106
2017
Q2
$11.7M Buy
165,663
+7,093
+4% +$472K 0.08% 105
2017
Q1
$10.8M Buy
158,570
+4,028
+3% +$283K 0.07% 113
2016
Q4
$11.1M Buy
154,542
+1,729
+1% +$129K 0.08% 106
2016
Q3
$12.1M Sell
152,813
-18,411
-11% -$1.5M 0.09% 102
2016
Q2
$14.3M Sell
171,224
-1,948
-1% -$173K 0.11% 91
2016
Q1
$15.9M Sell
173,172
-4,703
-3% -$424K 0.12% 82
2015
Q4
$18M Sell
177,875
-3,660
-2% -$381K 0.15% 77
2015
Q3
$17.8M Sell
181,535
-4,219
-2% -$469K 0.14% 73
2015
Q2
$21.7M Buy
185,754
+9,137
+5% +$998K 0.15% 69
2015
Q1
$17.3M Buy
176,617
+6,637
+4% +$674K 0.12% 74
2014
Q4
$16M Sell
169,980
-32,288
-16% -$3.34M 0.11% 76
2014
Q3
$21.5M Sell
202,268
-98,631
-33% -$9.66M 0.13% 69
2014
Q2
$24.9M Sell
300,899
-18,887
-6% -$1.47M 0.14% 66
2014
Q1
$22.7M Sell
319,786
-10,093
-3% -$792K 0.13% 72
2013
Q4
$24.8M Sell
329,879
-17,107
-5% -$1.19M 0.15% 61
2013
Q3
$21.8M Sell
346,986
-330,142
-49% -$19.7M 0.14% 66
2013
Q2
$34.7M Buy
+677,128
New +$35.3M 0.24% 43

Other funds holding GILD

CIBC Asset Management's GILD Position: Q2 2026 in Review

CIBC Asset Management increased its Gilead Sciences (GILD) stake by 28% in Q2 2026, buying an estimated $19.1M and bringing the position to 664,533 shares worth $84M. The position accounts for 0.18% of the portfolio, ranked #101.

CIBC Asset Management first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • CIBC Asset Management held 664,533 shares of Gilead Sciences worth $84M as of Q2 2026.
  • CIBC Asset Management bought 144,752 Gilead Sciences shares in Q2 2026, an estimated $19.1M.
  • Gilead Sciences made up 0.18% of CIBC Asset Management's portfolio in Q2 2026, its #101 holding.
  • CIBC Asset Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on CIBC Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.